Animal models are essential tools for understanding the pathogenesis of Progressive Supranuclear Palsy (PSP) and developing therapeutic interventions. Unlike Alzheimer's disease and Parkinson's disease, which have well-established animal models, PSP has presented unique challenges due to the selective vulnerability of specific neuronal populations and the 4R-tau pathology that characterizes the disease. This page provides a comprehensive overview of animal models used in PSP research, including their strengths, limitations, and contributions to our understanding of disease mechanisms.
PSP presents several unique challenges that make animal model development particularly difficult:
- 4R-Tau Specificity: PSP is characterized by exclusive accumulation of 4-repeat (4R) tau isoforms, while most transgenic models produce mixed 3R/4R tau
- Selective Neuronal Vulnerability: Specific populations are affected (globus pallidus, subthalamic nucleus, substantia nigra pars compacta, brainstem nuclei)
- Tau Strain Biology: PSP tau has distinct structural properties different from AD tau or CBD tau
- Age-Dependent Onset: PSP typically presents in the sixth decade, requiring age-appropriate model systems
Animal models enable researchers to:
- Study disease initiation and progression mechanisms
- Test therapeutic interventions before human trials
- Investigate regional vulnerability patterns
- Examine cell-type specific pathology
- Validate biomarkers and therapeutic targets
The P301L mutation in MAPT ( microtubule-associated protein tau) was first identified in frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) and has been extensively used in tauopathy research:
Several groups have developed models specifically expressing 4R tau:
Recent advances have enabled precise genetic knock-in:
- MAPT KI models: Endogenous mouse MAPT replaced with human MAPT variants
- Express physiological levels of tau
- Avoid overexpression artifacts
- Currently being developed for PSP-specific mutations
Adeno-associated virus (AAV) vectors allow localized, cell-type specific tau expression:
Recent models exploit the prion-like propagation of tau pathology:
- Inoculation models: Brain homogenate from PSP brains injected into rodents
- Shows templated tau pathology
- Demonstrates strain-specific propagation
- Technical challenges with species barriers
Rabbits have been used for tauopathy research due to their closer physiology to humans:
- Tau transgenic rabbits: Express human tau isoforms
- Develop age-dependent tau pathology
- Show some features of 4R tau accumulation
- Useful for studying cerebrovascular interactions
Ferrets offer advantages for studying brainstem circuitry:
- Natural susceptibility to 4R tau: Ferrets express predominantly 4R tau naturally
- Brainstem architecture: Similar organization to human brainstem nuclei
- Behavioral readouts: Well-characterized motor and cognitive behaviors
Non-human primates (NHPs) provide the closest models to human physiology:
- Cynomolgus macaques: Used for aging studies
- Rhesus macaques: Extensive neuroanatomical characterization
- AAV-mediated tau expression: Targeted injection into NHP brain
- Transgenic NHPs: Limited due to long generation times and ethical considerations
- Regional vulnerability patterns: Confirm GPi, STN, SNc susceptibility
- Tau isoform expression: 4R tau predominance in affected regions
- Therapeutic testing: Safety and efficacy of immunotherapies
C. elegans offers rapid, cost-effective modeling:
- Expression of human tau: Pan-neuronal or tissue-specific promoters
- Show tau phosphorylation and aggregation
- Display behavioral deficits
- Used for genetic screens
- Rapid generation time (3-4 days)
- Well-characterized nervous system
- Genetic tractability
- Suitable for high-throughput screening
- Simplified brain architecture
- Lacks mammalian-specific tau isoforms
- Short lifespan limits age-dependent studies
Fruit flies provide powerful genetic tools:
- Expression of human tau isoforms: Using GAL4/UAS system
- Neuron-specific expression possible
- Show tau-induced neurodegeneration
- Behavioral readouts available
- Kinase/phosphatase modifiers: Identify modifiers of tau toxicity
- Aggregation inhibitors: Screen for compounds reducing aggregation
- Autophagy modulators: Study protein clearance pathways
- 4R tau expression: Drosophila can be engineered to express 4R tau
- Mutation studies: Test specific MAPT mutations found in PSP
Zebrafish offer unique advantages for developmental and neurobiological studies:
- Transient expression: mRNA injection for temporary expression
- Stable transgenics: Tissue-specific promoters
- Crisis behavior: High throughput drug screening
- Transparent embryos for imaging
- Rapid development
- Genetic conservation with mammals
- Behavioral assays available
| Model Type |
Species |
Advantages |
Limitations |
PSP Relevance |
| Transgenic mouse |
Mouse |
Genetic manipulation, aged studies |
Mixed 3R/4R tau, overexpression |
Moderate |
| AAV injection |
Mouse/Rat |
Regional targeting, 4R expression |
Variable expression |
High |
| Knock-in mouse |
Mouse |
Physiological expression |
Long development time |
High |
| Rabbit |
Rabbit |
Intermediate complexity |
Limited genetic tools |
Moderate |
| Non-human primate |
Monkey |
Closest to human |
Cost, ethics |
Very high |
| C. elegans |
Worm |
Rapid, genetic screens |
Simplified system |
Low |
| Drosophila |
Fly |
Genetic tools, screens |
Evolutionary distance |
Moderate |
| Zebrafish |
Fish |
Developmental studies |
Limited aging studies |
Moderate |
-
Tau phosphorylation and aggregation
- NFT-like formations in neurons
- Tau-positive glial inclusions
- Insoluble tau fraction accumulation
-
Neurodegeneration
- Neuronal loss in targeted regions
- Axonal degeneration
- Synaptic dysfunction
-
Motor deficits
- Gait abnormalities
- Motor coordination deficits
- Reduced locomotor activity
-
Neuroinflammation
- Microglial activation
- Astrocytosis
- Cytokine expression
- 4R-tau specificity: Most models produce mixed isoforms
- Selective neuronal vulnerability: Regional specificity not fully achieved
- Human tau strain properties: Structural differences remain
- Disease duration: Shortened lifespan limits progression studies
- Tau vaccines: Anti-tau antibody generation
- ACI-35 (phospho-tau vaccine) tested in Phase I/II
- Shows clearance of tau pathology in mouse models
- Anti-tau antibodies: Direct antibody administration
- Several antibodies in clinical trials
- Demonstrated efficacy in mouse models
- Tau aggregation inhibitors: Methylene blue derivatives
- Kinase inhibitors: GSK-3β, CDK5 inhibitors
- OGA inhibitors: Increase tau O-GlcNAcylation
- Antisense oligonucleotides: Reduce MAPT expression
- Gene editing: CRISPR-based approaches
- Viral vector delivery: Targeted expression of therapeutic proteins
¶ Emerging Models and Future Directions
- Human tau knock-in mice: Physiological expression
- Chimeric models: Human neurons in mouse brain
- Brain organoids: 3D neural cultures
- PSP tau strains: Inoculation with patient-derived tau
- Synthetic strains: Defined structural variants
- Strain banking: Repository of characterized strains
- Optogenetic models: Light-controlled tau expression
- Chemogenetic models: Designer receptors activated by designer drugs
- Viral tracing: Mapping affected circuits
Note: This page previously contained references with unverifiable DOIs. References section pending update with verified citations.